IMMUNE NETWORK

  • 제10권6호
  • /
  • Pages.206-211
  • /
  • 2010
  • /
  • 1598-2629(pISSN)
  • /
  • 2092-6685(eISSN)
대한면역학회 (The Korean Association of Immunobiologists)
권호 표지
DOI QR코드

DOI QR Code

Induction of 90K-specific Cytotoxic T Lymphocytes for Colon Cancer Immunotherapy

  • Lee, Ji-Hee (Department of Oncology, Chonnam National University Hwasun Hospital) ;
  • Park, Myung-Suk (Department of Oncology, Chonnam National University Hwasun Hospital) ;
  • Chung, Ik-Joo (Department of Oncology, Chonnam National University Hwasun Hospital)
  • 투고 : 2010.11.02
  • 심사 : 2010.11.15
  • 발행 : 2010.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Dendritic cell (DC)-based tumor vaccine is an attractive modality for the treatment of colon cancer because it has been recurred and produced few side effects in patients. Secretory glycoprotein 90K has been found at elevated level in various cancer tissues and sera. We investigated to establish a more effective DC vaccine for the treatment of colon cancer in which the levels of 90K are elevated. Methods: We obtained the concentrated 90K from 293T cells stably expressing 90K. DCs were cultured from peripheral blood monocytes, and a DC vaccine pulsed with tumor lysate was compared with a DC vaccine pulsed with 90K. We measured the functional activity for CTLs by using IFN-${\gamma}$-enzyme linked immunoabsorbent spot (ELISPOT) assay. Results: DCs pulsed with tumor lysate+90K exhibited the enhanced T cell stimulation, polarization of $\ddot{i}$ T cell toward Th1. The CTLs generated by DCs pulsed with 90K efficiently lysed HCT116 cells. The results indicate that 90K-speicifc-CTLs can recognize 90K proteins naturally presented by colon cancer cells. Conclusion: Our study suggests that 90K-specific CTLs generated by 90K-pulsed DCs could be useful effector cells for immunotherapy in colon cancer.

키워드

참고문헌

  1. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392;245-252, 1998 https://doi.org/10.1038/32588
  2. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol 18;767-811, 2000 https://doi.org/10.1146/annurev.immunol.18.1.767
  3. Steinman RM, Dhodapkar M: Active immunization against cancer with dendritic cells: the near future. Int J Cancer 94;459-473, 2001 https://doi.org/10.1002/ijc.1503
  4. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183;87-97, 1996 https://doi.org/10.1084/jem.183.1.87
  5. Kaplan JM, Yu Q, Piraino ST, Pennington SE, Shankara S, Woodworth LA, Roberts BL: Induction of antitumor immunity with dendritic cells transduced with adenovirus vector- encoding endogenous tumor-associated antigens. J Immunol 163;699-707, 1999
  6. Iacobelli S, Arno E, D'Orazio A, Coletti G: Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res 46;3005-3010, 1986
  7. Rosenberg I, Cherayil BJ, Isselbacher KJ, Pillai S: Mac-2- binding glycoproteins. Putative ligands for a cytosolic beta- galactoside lectin. J Biol Chem 266;18731-18736,1991
  8. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A: Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem 268;14245-14249, 1993
  9. Ullrich A, Sures I, D'Egidio M, Jallal B, Powell TJ, Herbst R, Dreps A, Azam M, Rubinstein M, Natoli C, et al: The secreted tumor-associated antigen 90K is a potent immune stimulator. J Biol Chem 269;18401-18407, 1994
  10. Iacovazzi PA, Trisolini A, Barletta D, Elba S, Manghisi OG, Correale M: Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alpha-fetoprotein. Clin Chem Lab Med 39;961- 965, 2001 https://doi.org/10.1515/CCLM.2001.155
  11. Fusco O, Querzoli P, Nenci I, Natoli C, Brakebush C, Ullrich A, Iacobelli S: 90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells. Int J Cancer 79;23-26, 1998 https://doi.org/10.1002/(SICI)1097-0215(19980220)79:1<23::AID-IJC5>3.0.CO;2-Y
  12. Park YP, Choi SC, Kim JH, Song EY, Kim JW, Yoon DY, Yeom YI, Lim JS, Kim JW, Paik SG, Lee HG: Up-regulation of Mac-2 binding protein by hTERT in gastric cancer. Int J Cancer 120;813-820, 2007 https://doi.org/10.1002/ijc.22369
  13. Ozaki Y, Kontani K, Hanaoka J, Chano T, Teramoto K, Tezuka N, Sawai S, Fujino S, Yoshiki T, Okabe H, Ohkubo I: Expression and immunogenicity of a tumor-associated antigen, 90K/Mac-2 binding protein, in lung carcinoma. Cancer 95;1954-1962, 2002 https://doi.org/10.1002/cncr.10899
  14. Becker R, Lenter MC, Vollkommer T, Boos AM, Pfaff D, Augustin HG, Christian S: Tumor stroma marker endosialin (Tem1) is a binding partner of metastasis-related protein Mac-2 BP/90K. FASEB J 22;3059-3067, 2008 https://doi.org/10.1096/fj.07-101386
  15. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, et al: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1;1297-1302, 1995 https://doi.org/10.1038/nm1295-1297
  16. Porgador A, Gillboa E: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182;255-260, 1995 https://doi.org/10.1084/jem.182.1.255
  17. Boczkowski D, Nair SK, Snyder D, Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184;465-472, 1996 https://doi.org/10.1084/jem.184.2.465
  18. Boczkowski D, Nair SK, Snyder D, Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184;465-472, 1996 https://doi.org/10.1084/jem.184.2.465

피인용 문헌

  1. Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K vol.10, pp.3, 2010, https://doi.org/10.1038/cmi.2012.74
  2. Review on the immunotherapy strategies against metastatic colorectal carcinoma vol.8, pp.10, 2010, https://doi.org/10.2217/imt-2016-0045
  3. Immunocyte Profiling Using Single-Cell Mass Cytometry Reveals EpCAM+ CD4+ T Cells Abnormal in Colon Cancer vol.10, pp.None, 2010, https://doi.org/10.3389/fimmu.2019.01571
  4. Lgals3bp suppresses colon inflammation and tumorigenesis through the downregulation of TAK1-NF-κB signaling vol.7, pp.1, 2010, https://doi.org/10.1038/s41420-021-00447-7